Loading clinical trials...
Loading clinical trials...
A Phase II Single-arm Study for the Treatment After Recurrence of Advanced Melanoma Patients Harboring the V600BRAF Mutation and Pretreated With Vemurafenib, With the Association of Vemurafenib Plus Fotemustine.
Conditions
Interventions
Fotemustine + Vemurafenib
Locations
2
Italy
Paola Queirolo
Genova, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori "G.Pascale"
Naples, Italy
Start Date
February 1, 2013
Primary Completion Date
April 1, 2014
Completion Date
September 1, 2015
Last Updated
January 20, 2016
NCT03493230
NCT01676779
NCT03132090
NCT00722098
Lead Sponsor
Paola Queirolo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions